



PATENT

Case Docket No. OASBIO.001C1

Date: June 12, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bob D. Brown and Timothy R. Riley
Appl. No. : 09/931,732
Filed : August 16, 2001
For : ANTISENSE
OLIGONUCLEOTIDES
COMPRISING UNIVERSAL
AND/OR DEGENERATE
BASES
Examiner : Janet L. Epps-Ford, Ph.D.
Group Art Unit : 1635

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 12, 2003

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664


TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with ten (10) references, which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bob D. Brown and Timothy A. Riley
App. No. : 09/931,732
Filed : August 16, 2001
For : ANTISENSE OLIGONUCLEOTIDES
COMPRISING UNIVERSAL AND/OR
DEGENERATE BASES
Examiner : Janet L. Epps-Ford, Ph.D.
Group Art Unit : 1635

RECEIVED
JUN 18 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing ten (10) references that are also enclosed. This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth below in 37 C.F.R. § 1.97(c).

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than 30 days days/months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 12, 2003

By: Eric S. Furman

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
OASBIO 001C1APPLICATION NO.
09 931.732SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Bob D. Brown and Timothy A. RileyFILING DATE
August 16, 2001GROUP
1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	WO 93/10103	05/27/93	PCT				
	2.	WO 94/06810	03/31/94	PCT				
	3.	WO 94/09129	04/28/94	PCT				
	4.	WO 97/33991	09/18/97	PCT				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	5.	Altmann, et al., "Novel Chemistry," <i>Applied Antisense Oligonucleotide Technology</i> , Chapter 4, pp.73-107 (1998)
	6.	Hill, et al., "Polymerase recognition of synthetic oligodeoxyribonucleotides incorporating degenerate pyrimidine and purine bases," <i>Proc. Natl. Acad. Sci. USA</i> , 95:4258-4263 (1998)
	7.	Parker, et al., "Ribozymes: Principles and Designs for Their Use as Antisense and Therapeutic Agents," <i>Gene Regulation: Biology of Antisense RNA and DNA</i> , New York, Raven Press, pp. 55-70 (1992)
	8.	Sanghvi, "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides," <i>Antisense Research and Applications</i> , CRC Press, GB, Chapter 15, pp. 273-288 (1993)
	9.	Thomson, et al., "Universal Base Analogs in Antisense Oligodeoxynucleotides (as ODNs): A Therapeutic Strategy Against HIV Variability," <i>Human Retroviruses and Related Infections</i> , p. 143 (1995)
	10	David M. Tidd, "Ribonuclease H-Mediated Antisense Effects of Oligonucleotides and Controls for Antisense Experiments," <i>Applied Antisense Oligonucleotide Technology</i> , Chapter 8, pp. 161-171 (1998)

S:\DOCS\IESF\ESF-6716.DOC
060403

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.